Fabrinet vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Fabrinet trades at $383 (market cap $14.08B), while GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.2× Fabrinet's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | GEHC | |
|---|---|---|
Market Cap | $14.08B | $30.93B |
Volume | 1,319,574 | 5,033,451 |
Sector | Technology | Health |
52-Week High | $746.47 | $88.16 |
52-Week Low | $374.91 | $59.48 |
Typical Hold Time | 31 Days | — |
Enterprise Value | $13.21B | $39.39B |
Dividend Yield | — | 0.23% |
Signals from Pluang's Aura AI — not financial advice
FN trades at $427.82, down 6.26% over 24 hours, with a bullish technical signal despite near-term moving average weakness. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.10 exceeding expectations. Revenue grew to $3.42 billion in 2025, with net income of $332.53 million, and is projected to reach $4.6 billion in 2026. Analyst sentiment is positive, with 75% recommending Buy.
Outlook remains favorable due to surging AI data center demand and capacity expansion, though risks include customer concentration and high capital expenditures. The consensus price target of $769.50 implies significant upside, but investors should monitor margin pressures and competitive dynamics in the optical manufacturing sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →